Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
A Delaware District Court sided with Arbutus Biopharma Corporation (NASDAQ:ABUS) and Genevant Sciences in their ongoing patent infringement case against Moderna Inc (NASDAQ:MRNA) COVID-19 vaccine.
特拉華州地方法院支持Arbutus Biopharma Corporation（納斯達克股票代碼：ABUS）和Genevant Sciences正在進行的針對Moderna Inc（納斯達克股票代碼：MRNA）COVID-19 疫苗的專利侵權訴訟。
The companies jointly submitted a claim construction brief to the Delaware district court, seeking clarification on the patent's contested terms. They aim to define the meaning and extent of their patent claims precisely.
兩家公司共同向特拉華州地方法院提交了索賠解釋摘要，要求澄清該專利的爭議條款。他們的目標是精確地定義其專利權利要求的含義和範圍。
The District Court of Delaware released its decision on Wednesday, April 3.
特拉華州地方法院於4月3日星期三發佈了裁決。
Through the order, Judge Mitchell S. Goldberg broke down the language and the science used in each of the three claims, landing on definitions that served to strengthen the plaintiff's case by essentially rejecting Moderna's proposed constructions.
通過該命令，米切爾·戈德堡法官分解了三項索賠中使用的語言和科學原理，得出的定義基本上駁回了Moderna的擬議結構，從而強化了原告的案情。
In 2022, Arbutus Biopharma and Genevant sued Moderna for infringing on their patent on a lipid nanoparticle platform that they say was crucial to the delivery of Moderna's widely-used COVID-19 vaccine.
2022年，Arbutus Biopharma和Genevant起訴莫德納，指控其侵犯了他們在脂質納米顆粒平台上的專利，他們說該平台對莫德納廣泛使用的 COVID-19 疫苗的交付至關重要。
Arbutus and Genevant Sciences are seeking fair compensation for Moderna's use of its patented lipid nanoparticle (LNP) technology, without which Moderna's COVID-19 vaccine would not have been successful, the company said.
該公司表示，Arbutus和Genevant Sciences正在爲Moderna使用其專利脂質納米顆粒（LNP）技術尋求公平的補償，沒有這種技術，Moderna的 COVID-19 疫苗就不會成功。
JMP writes that the rest of the year consists of continued discovery and expert testimony, with a potential summary judgment in December, according to the current schedule.
JMP寫道，今年餘下的時間包括持續的發現和專家的證詞，根據目前的時間表，可能在12月作出簡易判決。
JMP Securities reiterates the Market Outperform rating with a price target of $4 on Arbutus Biopharma.
JMP證券重申Arbutus Biopharma的市場跑贏大盤評級，目標股價爲4美元。
Price Action: ABUS shares are up 3.25% at $3.02, and MRNA stock is up 3.89% at $105.2 on the last check Thursday.
價格走勢：週四的最後一次支票中，ABUS股價上漲3.25％，至3.02美元，MRNA股價上漲3.89％，至105.2美元。
譯文內容由第三人軟體翻譯。